ARTICLE | Clinical News
M2e/NP-ISS: Phase Ib started
October 4, 2010 7:00 AM UTC
Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: M2e/NP-ISS ( N8295) Business: Infectious Molecular target: Matrix protein 2 extracellular domain (M2e) Description: Immunostimulat...